Reduction

Tonix Pharmaceuticals Announces Two Poster Presentations of TNX-102 SL (Sublingual Cyclobenzaprine HCl) at the ASCP Annual Meeting

Retrieved on: 
torsdag, maj 30, 2024
NDA, FDA, Trauma, Reduction, PTSD, ASD, Week, COVID, ASCP, Therapy, Disability, Infection, Cocaine, Psychiatry, New Drug Application, Sleep, Sumatriptan, ASR, Autoimmunity, CNS, OASIS, Security (finance), Tonix Pharmaceuticals, Military personnel, Insomnia, Food, Safety, Long, Research, Cancer, Fatigue, Annual report, PROMIS, Society, Cognition, Failure, Science, Fibromyalgia, Patient, Risk, Government, Breakthrough therapy, CD40L, Health, Acute stress disorder, Observation, Veteran, Central nervous system, Disease, Annual general meeting, Pharmaceutical industry

CHATHAM, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced two poster presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held May 28-31, 2024 in Miami Beach, Fla. Copies of the presentations are available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.

Key Points: 
  • Copies of the presentations are available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com .
  • TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies and no new safety signals observed.
  • Previous trials of TNX-102 SL showed that it reduced military PTSD symptoms in as early as two weeks with favorable tolerability.
  • Randomized clinical trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related PTSD and the role of sleep quality in treatment response.

Tonix Pharmaceuticals to Deliver an Oral Presentation and Present Two Posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Retrieved on: 
onsdag, maj 22, 2024
Security (finance), Sleep, Sumatriptan, Risk, Food, NDA, Disease, University, ASR, FDA, Autoimmunity, Breakthrough therapy, Government, Reduction, Long, CD40L, Research, Cancer, Annual general meeting, CBP, CNS, Fatigue, Annual report, Acute stress disorder, ASCP, Society, Anxiety, Therapy, Infection, Cognition, Failure, Central nervous system, Cocaine, Science, OASIS, Pharmaceutical industry

CHATHAM, N.J., May 22, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company will deliver an oral presentation and present two posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held May 28-31, 2024 at the Loews Miami Beach Hotel in Miami Beach, Fla.

Key Points: 
  • The oral presentation will detail findings of studies of Tonmya (TNX-102 SL, sublingual cyclobenzaprine HCl) in fibromyalgia.
  • One poster will describe the Phase 2 proof of concept study of TNX-102 SL in fibromyalgia-type Long COVID.
  • TNX-102 SL is a centrally acting, non-opioid medication, which is trade named Tonmya™ for the management of fibromyalgia.
  • Copies of the Company’s presentation and posters will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.

Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)

Retrieved on: 
torsdag, maj 16, 2024
Perception, Patient, CSR, RD, Comorbidity, Food, Dialysis, PAI, National Kidney Foundation, Ageing, CDN, Reduction, Safety, Nephrology, AUC, Chronic kidney disease, MD, CKD, Hyperphosphatemia, Sevelamer, Post hoc analysis, NKF, Pharmaceutical industry

Ardelyx is also hosting an Exhibitor Showcase discussing hyperphosphatemia management.

Key Points: 
  • Ardelyx is also hosting an Exhibitor Showcase discussing hyperphosphatemia management.
  • XPHOZAH offers a different mechanism of action that blocks phosphate absorption at the primary pathway and is administered as a single tablet taken twice daily.
  • Tenapanor demonstrated similar efficacy and safety profiles in adult patients on dialysis regardless of age group and comorbidity.
  • In the Phase 3 study OPTIMIZE, 80% of patients enrolled answered a question characterizing their phosphate management regimen as improved, unchanged or worsened on tenapanor.

Powering America’s Commercial Transportation (PACT) Announces 24 Founding Members at ACT Expo

Retrieved on: 
onsdag, maj 22, 2024
Utilities, Alternative Energy, General Automotive, Energy, White House, Federal Government, Automotive, State, Local, Other Policy Issues, Trucking, Transport, Automotive Manufacturing, Public Policy, Government, Manufacturing, ACT, Burns & McDonnell, Legislation, Education, ZEVS, Commercial, Reduction, ABB, McDonnell Aircraft Corporation, Penske Truck Leasing, Federation, Federal Highway Administration, PACT, Navistar, BC Hydro, Multimedia, Daimler Truck North America, Renewable energy

Powering America’s Commercial Transportation (“PACT”) , a coalition focused on education and advocacy for accelerating the deployment of nationwide infrastructure for medium- and heavy-duty (M/HD) zero-emission vehicles (ZEVs), announced its list of founding members during ACT Expo in Las Vegas, Nevada.

Key Points: 
  • Powering America’s Commercial Transportation (“PACT”) , a coalition focused on education and advocacy for accelerating the deployment of nationwide infrastructure for medium- and heavy-duty (M/HD) zero-emission vehicles (ZEVs), announced its list of founding members during ACT Expo in Las Vegas, Nevada.
  • View the full release here: https://www.businesswire.com/news/home/20240522917556/en/
    Twenty-four leading companies from across commercial trucking and energy sectors come together to found PACT.
  • “We are all focused on accelerating the availability of reliable infrastructure for zero-emission commercial vehicles.
  • In service of this mission, PACT has intervened in legislative sessions and public utility commission and regulatory proceedings in multiple states.

Gulp Data Offers New Revenue Streams through Proprietary Data

Retrieved on: 
onsdag, maj 22, 2024
Professional Services, Data Management, Data Analytics, Technology, Software, Finance, Artificial Intelligence, Atomic emission spectroscopy, Growth, Layoff, IP, Reduction, Cryptocurrency

"Proprietary data is not just an asset -- it's the backbone of innovative and financially resilient business models," said Lauren Cascio, co-founder and CEO of Gulp Data. "This is the year of proprietary data, and we're focusing on helping companies unlock and monetize their unique data sets, thereby preserving equity positions and avoiding drastic measures like Reduction in Force (RIFs)."

Key Points: 
  • Gulp Data , a provider of data valuations, data-backed loans, and data monetization services, today highlighted the indispensable revenue streams proprietary data can provide in today’s venture capital drought.
  • "Proprietary data is not just an asset -- it's the backbone of innovative and financially resilient business models," said Lauren Cascio, co-founder and CEO of Gulp Data.
  • Gulp Data has conducted thousands of data valuations and helped over 500 companies identify hundreds of millions of dollars in data revenue.
  • Gulp Data simplifies the valuation process and provides strategic insights to transform and monetize existing data to drive growth and stability.

Converge Reports First Quarter 2024 Results

Retrieved on: 
torsdag, maj 9, 2024
AI, Converge, TSX, QC, Implement, Three Months, Managed services, Reduction, Adjustment, CTS

TORONTO, and GATINEAU, QC, May 9, 2024 /PRNewswire/ - Converge Technology Solutions Corp. ("Converge" or "the Company") (TSX:CTS) (FSE:0ZB) (OTCQX:CTSDF) is pleased to provide its financial results for the three month period ended March 31, 2024.

Key Points: 
  • TORONTO, and GATINEAU, QC, May 9, 2024 /PRNewswire/ - Converge Technology Solutions Corp. ("Converge" or "the Company") (TSX:CTS) (FSE:0ZB) (OTCQX:CTSDF) is pleased to provide its financial results for the three month period ended March 31, 2024.
  • All figures are in Canadian dollars unless otherwise stated.
  • "With our 3rd consecutive quarter of Billion-dollar sales and strong cash generation, we continue to demonstrate our position as a leading IT Service Provider," said Shaun Maine, Group CEO.
  • "Our Advise, Implement and Manage go-to-market strategy continues to drive our cross-sell efforts towards higher margin solutions and offerings across our key practice areas, demonstrated by our strong software sales during the quarter.

Converge Reports First Quarter 2024 Results

Retrieved on: 
torsdag, maj 9, 2024
AI, Converge, TSX, QC, Implement, Three Months, Managed services, Reduction, Adjustment, CTS

TORONTO, and GATINEAU, QC, May 9, 2024 /PRNewswire/ -- Converge Technology Solutions Corp. ("Converge" or "the Company") (TSX:CTS) (FSE:0ZB) (OTCQX:CTSDF) is pleased to provide its financial results for the three month period ended March 31, 2024. All figures are in Canadian dollars unless otherwise stated.

Key Points: 
  • TORONTO, and GATINEAU, QC, May 9, 2024 /PRNewswire/ -- Converge Technology Solutions Corp. ("Converge" or "the Company") (TSX:CTS) (FSE:0ZB) (OTCQX:CTSDF) is pleased to provide its financial results for the three month period ended March 31, 2024.
  • All figures are in Canadian dollars unless otherwise stated.
  • "With our 3rd consecutive quarter of Billion-dollar sales and strong cash generation, we continue to demonstrate our position as a leading IT Service Provider," said Shaun Maine, Group CEO.
  • "Our Advise, Implement and Manage go-to-market strategy continues to drive our cross-sell efforts towards higher margin solutions and offerings across our key practice areas, demonstrated by our strong software sales during the quarter.

Walden Biosciences Announces Positive Topline Data from Phase 1+ Clinical Study of WAL0921 in Development for Treatment of Kidney Diseases

Retrieved on: 
måndag, april 15, 2024
Receptor (biochemistry), Podocyte, Kidney disease, Safety, Kidney, Pharmacokinetics, Fibrinolysis, Trial of the century, Reduction, Dialysis, Monoclonal antibody, Pharmaceutical industry

CAMBRIDGE, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed clinical development stage company focused on disease-modifying, transformative therapies for the treatment of kidney diseases, today announced the results from the Company’s Phase 1+ clinical study of WAL0921 in healthy subjects. WAL0921 is Walden’s first-in-class, proprietary, humanized monoclonal antibody that binds circulating free soluble urokinase plasminogen activator receptor (suPAR) and its membrane bound form, uPAR, and inhibits their pathological activity, which causes kidney diseases.

Key Points: 
  • WAL0921 is Walden’s first-in-class, proprietary, humanized monoclonal antibody that binds circulating free soluble urokinase plasminogen activator receptor (suPAR) and its membrane bound form, uPAR, and inhibits their pathological activity, which causes kidney diseases.
  • The compromised kidney structure and function ultimately may lead to end-stage kidney disease requiring dialysis.
  • The Phase 1+ clinical study was a single center, placebo-controlled, single ascending dose study of WAL0921 in five cohorts that evaluated its safety, pharmacokinetics, and pharmacodynamics in 40 healthy subjects.
  • Data from the study showed that WAL0921 was safe, well-tolerated, and demonstrated proof-of-biology through a rapid, dose-dependent reduction in free suPAR levels.

Long Beach Container Terminal Receives $34.9 Million Federal Grant to Convert Fleet to Electric and Install Charging System

Retrieved on: 
fredag, april 26, 2024
Automotive, General Automotive, EV, Electric Vehicles, Logistics, Supply Chain Management, Transport, Alternative Vehicles, Fuels, Fleet Management, Climate change, Public, Investment, Ship, LEAP, Partnership, Carbon, LBCT, Reduction, San Pedro Bay, Movement, Blue Diamond Growers, Federal Highway Administration

Long Beach Container Terminal (LBCT) has received a $34.9 million Federal Highway Administration grant to replace more than 150 vehicles at its state-of-the-art cargo handling facility with zero-emission electric trucks and buses as well as to build the supporting charging infrastructure on site.

Key Points: 
  • Long Beach Container Terminal (LBCT) has received a $34.9 million Federal Highway Administration grant to replace more than 150 vehicles at its state-of-the-art cargo handling facility with zero-emission electric trucks and buses as well as to build the supporting charging infrastructure on site.
  • “LBCT is grateful for the support and leadership of Congressman Garcia in securing this grant.
  • These federal dollars will make our port cleaner, safer, and help us meet our climate goals,” said Congressman Garcia.
  • The grant was provided through the Reduction of Truck Emissions at Port Facilities program under President Biden’s Bipartisan Infrastructure Law.

Global and China Passenger Car T-Box Market Report 2024: China's Passenger Car T-Box Installations Jumped by 25.8% YoY, and LG, Neusoft and Denso still led - ResearchAndMarkets.com

Retrieved on: 
fredag, april 12, 2024
Software, Mobile, Wireless, Networks, Internet, IOT (Internet of Things), General Automotive, Technology, Automotive, 5G, Automotive Manufacturing, Other Automotive, Telecommunications, Manufacturing, FOTA, Safety, LG Electronics, ECall, MTK, Information technology, Gigabit Ethernet, V2X, Wi-Fi 6, Redcap, ETC, Neusoft, Communication, LG, Growth, Original equipment manufacturer, Attention, FD, Electronics, Intel, Denso, Ministry, Reduction, IOT, Security, T-box, 3GPP, RTMP, Huawei, DSDS, Renewable energy

The "Global and China Passenger Car T-Box Market Report, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global and China Passenger Car T-Box Market Report, 2024" report has been added to ResearchAndMarkets.com's offering.
  • China's passenger car T-Box installations jumped by 25.8% year on year, and LG, Neusoft and Denso still led.
  • From the perspective of competitive landscape, the market concentration declined, but leading players still had a big edge.
  • In 2023, the TOP 3 T-Box suppliers, LG, Neusoft and Denso, still led the T-Box market.